CA1304196C - Method of treating contact lenses - Google Patents
Method of treating contact lensesInfo
- Publication number
- CA1304196C CA1304196C CA000543513A CA543513A CA1304196C CA 1304196 C CA1304196 C CA 1304196C CA 000543513 A CA000543513 A CA 000543513A CA 543513 A CA543513 A CA 543513A CA 1304196 C CA1304196 C CA 1304196C
- Authority
- CA
- Canada
- Prior art keywords
- bendazac
- physiologically acceptable
- salt
- hydroxy
- inorganic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/05—Preparation of ethers by addition of compounds to unsaturated compounds
- C07C41/06—Preparation of ethers by addition of compounds to unsaturated compounds by addition of organic compounds only
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61L12/146—Aldehydes
Abstract
ABSTRACT
Treatment of contact lenses by an effective amount of bendazac ([(1-Benzyl-1H-indazol-3-yl)oxy]acetic acid), 5-hydroxy-bendazac or a salt thereof with a physiologically acceptable base.
Treatment of contact lenses by an effective amount of bendazac ([(1-Benzyl-1H-indazol-3-yl)oxy]acetic acid), 5-hydroxy-bendazac or a salt thereof with a physiologically acceptable base.
Description
~ - 2 -METHOD OF TREATING CONTACT LENSES
* * * * *
This ;nventlon relates to a method of treating contact lenses.
More particularly, it relates to the use of compounds which inhibit proteins sedimentation from lacrimal flu;d on contact lenses, preferably of the soft type, and neutralize possible proteins sediments without substantially affecting mucus secretion by mucous membranes.
It is known that soft contact lenses represent a progress in compar;son w;th r;gid ones in that they do not cause and do not transmit mechanical traumas to the eye. Nevertheless, they have the drawback of quickly undergoing opaqueness because of protein sediments from lacrimal fluid, the amount and nature of which are w;dely different from ind;vidual to indiv;dual.
Moreover~ very often, the sa;d protein sed;ments promote a keratoconjuct;val process of sens;t;zat;on wh;ch causes corneal irritat;on phenomena.
Several wash;ng techn;ques have been suggested for removing the above sa;d sed;ments, preferably by means oF solut;ons containirlg surfactants or enzymes.
These techniques, however, do not allow removing all the sed;ments and leave some residue wh;ch causes the above ment;oned drawbacks.
Therefore, a compund~;s st;ll in great demand capable of completely, or to a great extent, preventing the formation of protein sediments on contact lenses and which anyhow ;s capable of preventing the small sediment, so formed, from hav;ng sens;tizat;on properties.
It has been now found that the so called "Asp;r;n-l;ke"
~3~
compounds, that is the non-steroid ant;;nflammatory ac;d compounds, such as sal1cyl;c ac;d, phenylbutazone, ;buprofen and mefenamic acid, posses such propert;es.
These compounds, however, substant;ally reduce the amount of mucus secreted by mucous membranes~ Since mucus plays a very important role in protecting the eye, the so called "Aspirin-like" compounds result to be contraindicated for contacting the eye.
Furthermore, it has been now surpris;ngly found that bendazac, 5-hydroxy-bendazac and their salts w;th ;norganic or organic phys;ologically acceptable bases, inhibit sedimentation of proteins from lacrimal fluid on contact lenses and neutralize the ;rritative propert;es of possible protein sediments without substant;ally affecting the secretion of mucus by mucous membranes.
It is, therefore, an object of this invention to prov;de a method of treat;ng contact lenses, preferably of the soft type, comprising contacting a lens with an effect;ve amount of bendazac, 5-hydroxy-bendazac or a salt thereof with an organic or ;norganic phys;ologically base.
The compounds of formula:
R ~ O-CH2-COOH
N/N (I) CH ~
where R is H (bendazac) or OH (5-hydroxy-bendazac), and their salts with inorganic and organic physiologically acceptable ~.3~
bases, are already kr-own, for example from the Ital;an patent appticat;on Nr. 49,790 A/81 of November 27, 1981 and European patent application Nr. 191,520 of January 29, 1986 that describe their use as anticataract agents.
Examples of su;table bases are the alkali metals such as sodium and potassiurn, the al;phatic amines, the basic aminoacids such as lysine and arginine, and the l-ike.
Before being contacted w;th the lens, a compound of formula I or a physiologically acceptable salt thereof is preferably dissolved into a liquid~
The contact time of the solution comprising a compound of formula I or a physiologically acceptable salt thereof with a lens shall, of course, vary depending on the compound and the type of solution used. For instance, such time will be at least one hour in the case of deterging or wetting solutions, whereas it will be a few minutes in the case o-f rinsing solutions.
Another object of this invention is to provide the use of a compound of formula I or of a physilogically acceptable salt thereof for preparing solutions for the treatment of contact lenses.
The said solut;ons are prepared by d;ssolv;ng a compound of formula I or a physiologically acceptable salt thereof in a non -toxic solvent which is compatible with both the said compound and the lens and which is suitable for undergoing sterilization. Preferably, the said solvent consists of purified or distilled sterile water.
The solutions of this invention may also comprise other ingredients, the nature and amount of wh;ch vary depending on the type of solut;on to be prepared; this may indeed be ~L3~
~ - 5 -of a wetting, deterging, dis1nfecting or r;nsing type.
In the case of ind;viduals in which the compound of formula I used or ;ts physioLog;cally acceptable salt is not capable of inhibiting up to 100% of the formation of protein sediments, the solutions prepared according to this ;nvention are used together with solutions compr;sing surfactants or enzymes, or they themselves comprise surfactants and/or enzymes However the time for becoming opaque is much longer in the case of the lens thus treated than that observed, for the same individual, when the lens is treated with surfactants and/or enzymes alone and even the probability of the arising of corneal ;rr;tation ;s very reduced compared to that of the usual treatments.
Examples of other suitable ingredients are preservatives~
salts for regulating the osmotic pressure, antisept;cs, disin-fectants, antioxidants and buffers.
Said solutions may be easily prepared according to usual techniques which are well known to the people skilled in this art and comprise simple operations such as dissolv;ng and sterilization.
A further object of this invention ;s to provide aqueous solutions comprising an effect;ve amount of a compound of formula I or of a physioloyically acceptable salt thereof, which are su;table for wetting, deterging or rinsing contact lenses.
Typical examples of solut;ons according to this invention comprise a compound of formula I or a physiologically acceptable salt thereof and at least a disinfectant, a surfactant and/or an enzyme.
E~amples of suitable disinfectants, surfactants and enzymes 1 are chlorhexidine gluconate, octylphenoxyoctanol and papain, respectively.
Preferably the solutions according to this invention comprise from 0.05 to 2% of bendazac ([(l-Benzyl-lH-indazol-3-yl)oxy]acetic acid), or of 5-hydroxy-bendazac, or the corresponding amount of a salt with a phys.iologically acceptable organic or inorganic base.
The following examples are given to illustrate this invention without, however, limiting it in any way.
Wetting solution 100 ml contain:
Bendazac sodium salt 0.25 9 Hydroxy ethyl cellulose 0.4 9 Polyvinyl alcohoL 1.4 9 Thimerosal 0-004 9 Sodium edetate 0.20 9 Sodium chlor;de 0.75 9 Boric acid or borax to pH 7.4 Sterile distilled water q.s. to 100 ml Wettin~q solution 100 ml contain:
5-hydroxybendazac 0.25 9 Hydroxy ethyl cellulose 0.4 9 Polyvinlyl alcohol 1.4 9 Thimerosal 0.004 9 Sodium edetate 0.20 9 Sodium chloride 0.65 9 Anhydrous Sodium sulfite 0.15 9 1 N Sodium hydroxide to pH 6.5 * Trade Mark ~., ~L3~
Sterile distilled water q.s. to 100 ml Deter~ing solution 100 ~l contain:
~endazac sodium salt 0.25 9 Polivinyl alchol 1.4 9 Thimerosal 0-004 9 Sodium edetate 0.20 9 Sodium chloride 0.75 9 Octyl phenoxy ethanol 0.35 9 ~oric acid or borax to pH 7.4 Sterile distilled water q.s. to 100 ml Deterg;ng solution 100 ml contain:
5-hydroxybendazac 0.25 9 Polyvinyl alcohol 1.4 9 Thimer~sal 0 004 9 Sodium edetate 0.20 9 Sodium chlor;de 0.65 g Anhydrous Sodium sulfite 0.15 9 Octyl phenoxy ethanol 0.35 9 1 N Sodium hydrox;de to pH 6~5 Sterile dist;lled water q.s. to 100 ml EXAMPLE S
Disinfecting solut;on 100 ml contain:
aendazac sodium salt 0.25 9 - Sodium chlori:de 0.75 9 Thimerosal 0.001 9 * Trade Mark ~304~
Chlohrexid;ne gluconate O.OOS g Sodium edetate 0.1 Polysorbate 80 0.05 9 ; Boric acid or borax to pH 7.4 - 5 Sterile demineralized water q.s. to 100 ml Disinfecting solution 100 ml contain:
5-hydroxybendazac 0.25 CJ
Sodium chloride 0~65 9 Anhydrous Sodium sulfite 0.15 g Thimerosal 0 . 001 g Chlorhexid;ne gluconate 0.005 9 Sodium edetate 0.1 9 Polysorbate 80 0.05 9 Sterile dem;neralized water q.s. to 100 ml Solution for rinsing or thermal disinfection 100 ml contain:
Bendazac 0.25 9 Sodium chloride 0.75 9 Thimerosal 0.001 g Sodium edetate 0.1 9 Boric acid or borax to pH 7.4 . 25 Sterile demineralized water qOs. to 100 ml Solution for rinsing or thermal d;sinfection 100 ml contain:
5~hydroxybendazac 0.25 9 Sodium chloride 0.65 9 * Trade Mark ~ , ~^
Anhydrous Sod;um sulf;te 0.15 g Thimerosal 0.001 9 Sod;um edetate 0.1 1 N Sodium hydrox;de to pH 6.5 Sterile demineralized water q.s. to 100 ml Wetting solution 10Q ml contain:
Bendazac lysinate 0.4 9 Hydroxy ethyl cellulose 0.4 9 Polyv;nyl alcohol 1.4 9 Thimerosal 0 004 9 Sod;um edetate 0.2 Sod;um chloride 0.75 9 Bor;c acid or borax to pH 7.4 Sterile distilled water q.s. to 100 ml A first experiment has been carried out on six individuals ~earing soft contact lenses and specifically selected because they produced every 5-6 days such an amount o; sediments on the said lenses that they had to treat their lenses da;ly w;th a deterging composit;on containing a surfactan~, and weekly with a compos1t;on conta;ning a proteolytic enzyme.
These ind;v;duals stopped us;ng the composlt;on containing a proteolyt;c enzyme. For a period of three mcnths they regularly dipped their lenses in a solution according to example 9 every night after the usual deterg;ng and aisinfecting treatment. More particularly, the lenses ~ere kept in the above solution overnight.
In the course of the entire three months period~ all six individuals d;d not need to ciean their lenses with any * Trade Mark ),4 ~ .
, ..
~3~ 6 composition containing a proteolytic enzyme.
A second exper1ment has br-en carried out on ten ;ndividuals whose soft contact lenses showed appreciable sediments easily detectable, observing the lenses on a black background through S a 7-fold magnification. These individuals used the solution according to example 9 by contacting directly the worn lenses in situ with two drops of the said solution 4 times a day.
The regular use of the said solution for 14 consecu-tive days caused, in all ten individuals, disappearance or substantial reduction of the sediments on the lenses.
* * * * *
This ;nventlon relates to a method of treating contact lenses.
More particularly, it relates to the use of compounds which inhibit proteins sedimentation from lacrimal flu;d on contact lenses, preferably of the soft type, and neutralize possible proteins sediments without substantially affecting mucus secretion by mucous membranes.
It is known that soft contact lenses represent a progress in compar;son w;th r;gid ones in that they do not cause and do not transmit mechanical traumas to the eye. Nevertheless, they have the drawback of quickly undergoing opaqueness because of protein sediments from lacrimal fluid, the amount and nature of which are w;dely different from ind;vidual to indiv;dual.
Moreover~ very often, the sa;d protein sed;ments promote a keratoconjuct;val process of sens;t;zat;on wh;ch causes corneal irritat;on phenomena.
Several wash;ng techn;ques have been suggested for removing the above sa;d sed;ments, preferably by means oF solut;ons containirlg surfactants or enzymes.
These techniques, however, do not allow removing all the sed;ments and leave some residue wh;ch causes the above ment;oned drawbacks.
Therefore, a compund~;s st;ll in great demand capable of completely, or to a great extent, preventing the formation of protein sediments on contact lenses and which anyhow ;s capable of preventing the small sediment, so formed, from hav;ng sens;tizat;on properties.
It has been now found that the so called "Asp;r;n-l;ke"
~3~
compounds, that is the non-steroid ant;;nflammatory ac;d compounds, such as sal1cyl;c ac;d, phenylbutazone, ;buprofen and mefenamic acid, posses such propert;es.
These compounds, however, substant;ally reduce the amount of mucus secreted by mucous membranes~ Since mucus plays a very important role in protecting the eye, the so called "Aspirin-like" compounds result to be contraindicated for contacting the eye.
Furthermore, it has been now surpris;ngly found that bendazac, 5-hydroxy-bendazac and their salts w;th ;norganic or organic phys;ologically acceptable bases, inhibit sedimentation of proteins from lacrimal fluid on contact lenses and neutralize the ;rritative propert;es of possible protein sediments without substant;ally affecting the secretion of mucus by mucous membranes.
It is, therefore, an object of this invention to prov;de a method of treat;ng contact lenses, preferably of the soft type, comprising contacting a lens with an effect;ve amount of bendazac, 5-hydroxy-bendazac or a salt thereof with an organic or ;norganic phys;ologically base.
The compounds of formula:
R ~ O-CH2-COOH
N/N (I) CH ~
where R is H (bendazac) or OH (5-hydroxy-bendazac), and their salts with inorganic and organic physiologically acceptable ~.3~
bases, are already kr-own, for example from the Ital;an patent appticat;on Nr. 49,790 A/81 of November 27, 1981 and European patent application Nr. 191,520 of January 29, 1986 that describe their use as anticataract agents.
Examples of su;table bases are the alkali metals such as sodium and potassiurn, the al;phatic amines, the basic aminoacids such as lysine and arginine, and the l-ike.
Before being contacted w;th the lens, a compound of formula I or a physiologically acceptable salt thereof is preferably dissolved into a liquid~
The contact time of the solution comprising a compound of formula I or a physiologically acceptable salt thereof with a lens shall, of course, vary depending on the compound and the type of solution used. For instance, such time will be at least one hour in the case of deterging or wetting solutions, whereas it will be a few minutes in the case o-f rinsing solutions.
Another object of this invention is to provide the use of a compound of formula I or of a physilogically acceptable salt thereof for preparing solutions for the treatment of contact lenses.
The said solut;ons are prepared by d;ssolv;ng a compound of formula I or a physiologically acceptable salt thereof in a non -toxic solvent which is compatible with both the said compound and the lens and which is suitable for undergoing sterilization. Preferably, the said solvent consists of purified or distilled sterile water.
The solutions of this invention may also comprise other ingredients, the nature and amount of wh;ch vary depending on the type of solut;on to be prepared; this may indeed be ~L3~
~ - 5 -of a wetting, deterging, dis1nfecting or r;nsing type.
In the case of ind;viduals in which the compound of formula I used or ;ts physioLog;cally acceptable salt is not capable of inhibiting up to 100% of the formation of protein sediments, the solutions prepared according to this ;nvention are used together with solutions compr;sing surfactants or enzymes, or they themselves comprise surfactants and/or enzymes However the time for becoming opaque is much longer in the case of the lens thus treated than that observed, for the same individual, when the lens is treated with surfactants and/or enzymes alone and even the probability of the arising of corneal ;rr;tation ;s very reduced compared to that of the usual treatments.
Examples of other suitable ingredients are preservatives~
salts for regulating the osmotic pressure, antisept;cs, disin-fectants, antioxidants and buffers.
Said solutions may be easily prepared according to usual techniques which are well known to the people skilled in this art and comprise simple operations such as dissolv;ng and sterilization.
A further object of this invention ;s to provide aqueous solutions comprising an effect;ve amount of a compound of formula I or of a physioloyically acceptable salt thereof, which are su;table for wetting, deterging or rinsing contact lenses.
Typical examples of solut;ons according to this invention comprise a compound of formula I or a physiologically acceptable salt thereof and at least a disinfectant, a surfactant and/or an enzyme.
E~amples of suitable disinfectants, surfactants and enzymes 1 are chlorhexidine gluconate, octylphenoxyoctanol and papain, respectively.
Preferably the solutions according to this invention comprise from 0.05 to 2% of bendazac ([(l-Benzyl-lH-indazol-3-yl)oxy]acetic acid), or of 5-hydroxy-bendazac, or the corresponding amount of a salt with a phys.iologically acceptable organic or inorganic base.
The following examples are given to illustrate this invention without, however, limiting it in any way.
Wetting solution 100 ml contain:
Bendazac sodium salt 0.25 9 Hydroxy ethyl cellulose 0.4 9 Polyvinyl alcohoL 1.4 9 Thimerosal 0-004 9 Sodium edetate 0.20 9 Sodium chlor;de 0.75 9 Boric acid or borax to pH 7.4 Sterile distilled water q.s. to 100 ml Wettin~q solution 100 ml contain:
5-hydroxybendazac 0.25 9 Hydroxy ethyl cellulose 0.4 9 Polyvinlyl alcohol 1.4 9 Thimerosal 0.004 9 Sodium edetate 0.20 9 Sodium chloride 0.65 9 Anhydrous Sodium sulfite 0.15 9 1 N Sodium hydroxide to pH 6.5 * Trade Mark ~., ~L3~
Sterile distilled water q.s. to 100 ml Deter~ing solution 100 ~l contain:
~endazac sodium salt 0.25 9 Polivinyl alchol 1.4 9 Thimerosal 0-004 9 Sodium edetate 0.20 9 Sodium chloride 0.75 9 Octyl phenoxy ethanol 0.35 9 ~oric acid or borax to pH 7.4 Sterile distilled water q.s. to 100 ml Deterg;ng solution 100 ml contain:
5-hydroxybendazac 0.25 9 Polyvinyl alcohol 1.4 9 Thimer~sal 0 004 9 Sodium edetate 0.20 9 Sodium chlor;de 0.65 g Anhydrous Sodium sulfite 0.15 9 Octyl phenoxy ethanol 0.35 9 1 N Sodium hydrox;de to pH 6~5 Sterile dist;lled water q.s. to 100 ml EXAMPLE S
Disinfecting solut;on 100 ml contain:
aendazac sodium salt 0.25 9 - Sodium chlori:de 0.75 9 Thimerosal 0.001 9 * Trade Mark ~304~
Chlohrexid;ne gluconate O.OOS g Sodium edetate 0.1 Polysorbate 80 0.05 9 ; Boric acid or borax to pH 7.4 - 5 Sterile demineralized water q.s. to 100 ml Disinfecting solution 100 ml contain:
5-hydroxybendazac 0.25 CJ
Sodium chloride 0~65 9 Anhydrous Sodium sulfite 0.15 g Thimerosal 0 . 001 g Chlorhexid;ne gluconate 0.005 9 Sodium edetate 0.1 9 Polysorbate 80 0.05 9 Sterile dem;neralized water q.s. to 100 ml Solution for rinsing or thermal disinfection 100 ml contain:
Bendazac 0.25 9 Sodium chloride 0.75 9 Thimerosal 0.001 g Sodium edetate 0.1 9 Boric acid or borax to pH 7.4 . 25 Sterile demineralized water qOs. to 100 ml Solution for rinsing or thermal d;sinfection 100 ml contain:
5~hydroxybendazac 0.25 9 Sodium chloride 0.65 9 * Trade Mark ~ , ~^
Anhydrous Sod;um sulf;te 0.15 g Thimerosal 0.001 9 Sod;um edetate 0.1 1 N Sodium hydrox;de to pH 6.5 Sterile demineralized water q.s. to 100 ml Wetting solution 10Q ml contain:
Bendazac lysinate 0.4 9 Hydroxy ethyl cellulose 0.4 9 Polyv;nyl alcohol 1.4 9 Thimerosal 0 004 9 Sod;um edetate 0.2 Sod;um chloride 0.75 9 Bor;c acid or borax to pH 7.4 Sterile distilled water q.s. to 100 ml A first experiment has been carried out on six individuals ~earing soft contact lenses and specifically selected because they produced every 5-6 days such an amount o; sediments on the said lenses that they had to treat their lenses da;ly w;th a deterging composit;on containing a surfactan~, and weekly with a compos1t;on conta;ning a proteolytic enzyme.
These ind;v;duals stopped us;ng the composlt;on containing a proteolyt;c enzyme. For a period of three mcnths they regularly dipped their lenses in a solution according to example 9 every night after the usual deterg;ng and aisinfecting treatment. More particularly, the lenses ~ere kept in the above solution overnight.
In the course of the entire three months period~ all six individuals d;d not need to ciean their lenses with any * Trade Mark ),4 ~ .
, ..
~3~ 6 composition containing a proteolytic enzyme.
A second exper1ment has br-en carried out on ten ;ndividuals whose soft contact lenses showed appreciable sediments easily detectable, observing the lenses on a black background through S a 7-fold magnification. These individuals used the solution according to example 9 by contacting directly the worn lenses in situ with two drops of the said solution 4 times a day.
The regular use of the said solution for 14 consecu-tive days caused, in all ten individuals, disappearance or substantial reduction of the sediments on the lenses.
Claims (5)
1. A method of treating a contact lens wherein a lens is contacted with an effective amount of bendazac ([(1-Benzyl-1H-indazol-3-yl)oxy]acetic acid), 5-hydroxy-bendazac, or of a salt thereof with an inorganic or organic physiologically acceptable base.
2. A method according to claim 1, wherein a soft contact lens is contacted with a solution comprising from 0.05 to 2% of bendazac ([(1-Benzyl-1H-indazol-3-yl)oxy]
acetic acid), 5-hydroxy-bendazac or the corresponding amount of a salt thereof with an inorganic or organic physiologically acceptable base.
acetic acid), 5-hydroxy-bendazac or the corresponding amount of a salt thereof with an inorganic or organic physiologically acceptable base.
3. Use of bendazac ([(1-Benzyl-1H-indazol-3-yl)oxy]acetic acid), 5-hydroxy-bendazac and of a salt thereof with an inorganic or organic physiologically acceptable base for preparing a solution for treating soft contact lenses, which comprises from 0.05 to 2% of bendazac, or of 5-hydroxy-bendazac, or the corresponding amount of a salt thereof with an inorganic or organic physiologically acceptable base.
4. Use of a solution comprising from 0.05 to 2% of bendazac ([(1-Benzyl-1H-indazol-3-yl)oxy]acetic acid), or of 5-hydroxy-bendazac, or of a salt thereof with an inorganic or organic physiologically acceptable base, for treating contact lenses.
5. A method of inhibiting protein sedimentation from Lacrimal fluid on a contact lens and neutralizing irritative effect of existing protein sediments wherein said lens is contacted with an effective amount of a composition comprising bendazac ([(1-Benzyl-1H-indazol-3-yl)oxy]acetic acid), 5-hydroxy-bendazac, or a salt thereof with an inorganic or organic physiologically acceptable base, and a physiologically acceptable carrier said contact occurring prior to insertion of said lens into the eye.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT21384A/86 | 1986-08-01 | ||
| IT21384/86A IT1197805B (en) | 1986-08-01 | 1986-08-01 | METHOD FOR THE TREATMENT OF CONTACT LENSES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1304196C true CA1304196C (en) | 1992-06-30 |
Family
ID=11180969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000543513A Expired - Fee Related CA1304196C (en) | 1986-08-01 | 1987-07-31 | Method of treating contact lenses |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US4895676A (en) |
| EP (1) | EP0255967B1 (en) |
| JP (1) | JPH071353B2 (en) |
| KR (1) | KR960003515B1 (en) |
| AR (1) | AR244555A1 (en) |
| AT (1) | ATE71307T1 (en) |
| AU (1) | AU602708B2 (en) |
| BR (1) | BR8703930A (en) |
| CA (1) | CA1304196C (en) |
| DE (2) | DE255967T1 (en) |
| DK (1) | DK399987A (en) |
| ES (1) | ES2001836T3 (en) |
| GE (1) | GEP19971020B (en) |
| GR (2) | GR880300112T1 (en) |
| IE (1) | IE60590B1 (en) |
| IL (1) | IL83288A (en) |
| IN (1) | IN167360B (en) |
| IT (1) | IT1197805B (en) |
| LT (1) | LT3603B (en) |
| MX (1) | MX169432B (en) |
| NZ (1) | NZ221202A (en) |
| PH (1) | PH24060A (en) |
| PT (1) | PT85404B (en) |
| RU (1) | RU2001631C1 (en) |
| UA (1) | UA19674A (en) |
| ZA (1) | ZA875399B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1197805B (en) * | 1986-08-01 | 1988-12-06 | Acraf | METHOD FOR THE TREATMENT OF CONTACT LENSES |
| IT1230441B (en) | 1989-02-07 | 1991-10-23 | Acraf | ETHERS OF THE INDAZOLE SERIES |
| US5277708A (en) * | 1993-01-19 | 1994-01-11 | S&S Industrial Services, Inc. | Buffing composition |
| GB2278846B (en) * | 1993-06-10 | 1997-04-16 | Gen Electric | Fluorosilicone terpolymeric fluid |
| US5451237A (en) * | 1993-11-10 | 1995-09-19 | Vehige; Joseph G. | Compositions and methods for inhibiting and reducing lysozyme deposition on hydrophilic contact lenses using biocompatible colored compounds |
| IT1293794B1 (en) * | 1997-07-28 | 1999-03-10 | Acraf | DRUG ACTIVE IN REDUCING THE PRODUCTION OF MCP-1 PROTEIN |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1189052B (en) * | 1981-11-27 | 1988-01-28 | Acraf | CATARACT TREATMENT |
| GB8332489D0 (en) * | 1983-12-06 | 1984-01-11 | Contactasol Ltd | Contact lenses |
| EP0191520B1 (en) * | 1985-02-12 | 1989-06-21 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | (1-phenylmethyl-5-hydroxy-1h-indazol-3-yl)-oxyacetic acid and salts thereof for use as a medicament, and pharmaceutical compositions containing them |
| IT1197805B (en) * | 1986-08-01 | 1988-12-06 | Acraf | METHOD FOR THE TREATMENT OF CONTACT LENSES |
-
1986
- 1986-08-01 IT IT21384/86A patent/IT1197805B/en active
-
1987
- 1987-07-17 DE DE198787201369T patent/DE255967T1/en active Pending
- 1987-07-17 DE DE8787201369T patent/DE3775853D1/en not_active Expired - Fee Related
- 1987-07-17 AT AT87201369T patent/ATE71307T1/en not_active IP Right Cessation
- 1987-07-17 EP EP87201369A patent/EP0255967B1/en not_active Expired - Lifetime
- 1987-07-17 ES ES198787201369T patent/ES2001836T3/en not_active Expired - Lifetime
- 1987-07-22 AU AU76008/87A patent/AU602708B2/en not_active Ceased
- 1987-07-22 IN IN563/CAL/87A patent/IN167360B/en unknown
- 1987-07-22 IL IL83288A patent/IL83288A/en not_active IP Right Cessation
- 1987-07-22 ZA ZA875399A patent/ZA875399B/en unknown
- 1987-07-24 PT PT85404A patent/PT85404B/en not_active IP Right Cessation
- 1987-07-27 NZ NZ221202A patent/NZ221202A/en unknown
- 1987-07-29 PH PH35598A patent/PH24060A/en unknown
- 1987-07-30 BR BR8703930A patent/BR8703930A/en unknown
- 1987-07-31 AR AR87308314A patent/AR244555A1/en active
- 1987-07-31 RU SU874203152A patent/RU2001631C1/en active
- 1987-07-31 CA CA000543513A patent/CA1304196C/en not_active Expired - Fee Related
- 1987-07-31 IE IE208787A patent/IE60590B1/en not_active IP Right Cessation
- 1987-07-31 JP JP62193621A patent/JPH071353B2/en not_active Expired - Fee Related
- 1987-07-31 MX MX007555A patent/MX169432B/en unknown
- 1987-07-31 KR KR1019870008381A patent/KR960003515B1/en active IP Right Grant
- 1987-07-31 UA UA4203152A patent/UA19674A/en unknown
- 1987-07-31 DK DK399987A patent/DK399987A/en not_active Application Discontinuation
-
1988
- 1988-12-16 GR GR88300112T patent/GR880300112T1/en unknown
-
1989
- 1989-01-11 US US07/296,275 patent/US4895676A/en not_active Expired - Lifetime
- 1989-11-07 US US07/432,797 patent/US5013484A/en not_active Expired - Lifetime
-
1992
- 1992-02-04 GR GR920400139T patent/GR3003706T3/el unknown
-
1993
- 1993-07-26 GE GEAP19931212A patent/GEP19971020B/en unknown
- 1993-08-17 LT LTIP871A patent/LT3603B/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5494937A (en) | Saline solution for treating contact lenses | |
| EP0371728B1 (en) | Aqueous ophthalmic solutions and method for preserving same | |
| KR100262055B1 (en) | Contact lens solution preservative system | |
| JP4486895B2 (en) | Use of multifunctional surfactants to clean contact lenses | |
| EP0757095B1 (en) | Method of cleaning and disinfecting contact lens | |
| WO2003067311A1 (en) | Contact lens solution | |
| DK160033B (en) | Agent for cleaning dentine surfaces | |
| CA2244224C (en) | Dual neutralization system for iodine treatment of contact lenses | |
| EP0189405B1 (en) | Disinfection of contact lenses | |
| CA1304196C (en) | Method of treating contact lenses | |
| US4880601A (en) | Hydrogen peroxide disinfecting system for contact lenses | |
| US5571504A (en) | Method of stabilizing preparations for contact lenses | |
| EP0756874B1 (en) | Cleaning and disinfecting agent for contact lens and method for cleaning and disinfecting contact lens using the same | |
| US5627214A (en) | Use of diamines in ophthalmic compositions | |
| US5176714A (en) | Method of treating contact lenses | |
| JPS6175319A (en) | Contact lens detergent and cleaning method | |
| JPH11290429A (en) | Disinfecting, cleaning and preserving solution for contact lens and disinfecting and cleaning method therefor | |
| EP1792972A1 (en) | Use of multifuctional surface active agents to clean contact lenses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |